• GH Research posted a net loss of USD 34.11 million for the six months ended June 30, 2026, driven by higher operating costs.
• R&D expense rose to USD 24.78 million from USD 16.81 million, led by technical and clinical development spending, including trial costs.
• G&A expense increased to USD 13.43 million from USD 10.63 million, mainly reflecting higher professional fees.
• Net finance income fell to USD 4.69 million from USD 5.48 million due to lower investment returns.
• Cash, cash equivalents and marketable securities totaled USD 362.7 million, up from USD 280.7 million, supported by USD 111.2 million net equity-offering proceeds.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GH Research plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-031506), on August 06, 2026, and is solely responsible for the information contained therein.